19. The antibody or antigen-binding portion thereof of claim 18, wherein the antibody or antigen-binding portion thereof comprises a heavy chain region and a light chain region,

the heavy chain region comprising three CDRs, CDR1, CDR2, CDR3, having amino acid sequences about 80% to about 100% homologous to the amino acid sequences set forth in SEQ ID NOs: 29, 30 and 31, respectively,

the light chain region comprising three CDRs, CDR1, CDR2, CDR3, having amino acid sequences about 80% to about 100% homologous to the amino acid sequences set forth in SEQ ID NOs: 21, 22 and 23, respectively.

20. A composition comprising the antibody or antigen-binding portion thereof of claim 1, and at least one pharmaceutically acceptable carrier.

21. Use of an effective amount of the antibody or antigen-binding portion thereof of claim 1 in the manufacture of a medicament for preventing or treating C. difficile-associated disease.

22. The use of claim 21, wherein the antibody or antigen-binding portion thereof is to be administered intravenously, subcutaneously, intramuscularly or transdermally.

23. The use of claim 21, wherein the subject is to be a second agent.

24. The use of claim 23, wherein the second agent is a different antibody or fragment thereof.

25. The use of claim 23, wherein the second agent is an antibiotic.

26. The use of claim 25, wherein the antibiotic is vancomycin, metronidazole, or fidaxomicin.

19. The antibody or antigen-binding portion thereof of claim 18, wherein the antibody or antigen-binding portion thereof comprises a heavy chain region and a light chain region,

the heavy chain region comprising three CDRs, CDR1, CDR2, CDR3, having amino acid sequences about 80% to about 100% homologous to the amino acid sequences set forth in SEQ ID NOs: 29, 30 and 31, respectively,

the light chain region comprising three CDRs, CDR1, CDR2, CDR3, having amino acid sequences about 80% to about 100% homologous to the amino acid sequences set forth in SEQ ID NOs: 21, 22 and 23, respectively.

20. A composition comprising the antibody or antigen-binding portion thereof of claim 1, and at least one pharmaceutically acceptable carrier.

21. A method of preventing or treating *C. difficile*-associated disease comprising administering to a subject an effective amount of the antibody or antigen-binding portion thereof of claim 1.

22. The method of claim 21, wherein the antibody or antigen-binding portion thereof is administered intravenously, subcutaneously, intramuscularly or transdermally.

23. The method of claim 21, further comprising the step of administering to the subject a second agent.

24. The method of claim 23, wherein the second agent is a different antibody or fragment thereof.

25. The method of claim 23, wherein the second agent is an antibiotic.

26. The method of claim 25, wherein the antibiotic is vancomycin, metronidazole, or fidaxomicin.